These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21952916)

  • 1. Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease.
    Banati M; Hosszu Z; Trauninger A; Szereday L; Illes Z
    Muscle Nerve; 2011 Nov; 44(5):720-6. PubMed ID: 21952916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis.
    Schuerwegh AJ; van Offel JF; Bridts CH; Stevens WJ; De Clerck LS
    J Rheumatol; 2001 Aug; 28(8):1793-9. PubMed ID: 11508581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 8. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y; Thoburn CJ; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
    Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct pattern of IL-2 and IFN-gamma gene expression in CD4 and CD8 T cells: cytofluorometric analysis at a single cell level using non-radioactive probes.
    Morvan PY; Picot C; Dejour R; Genetet B; Genetet N
    Cell Mol Biol (Noisy-le-grand); 1995 Nov; 41(7):945-57. PubMed ID: 8595373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease.
    Bodolay E; Aleksza M; Antal-Szalmás P; Végh J; Szodoray P; Soltész P; Szegedi A; Szekanecz Z
    J Rheumatol; 2002 Oct; 29(10):2136-42. PubMed ID: 12375323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
    Hunley TE; Corzo D; Dudek M; Kishnani P; Amalfitano A; Chen YT; Richards SM; Phillips JA; Fogo AB; Tiller GE
    Pediatrics; 2004 Oct; 114(4):e532-5. PubMed ID: 15466083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine secretion by C3H-lpr and -gld T cells. Hypersecretion of IFN-gamma and tumor necrosis factor-alpha by stimulated CD4+ T cells.
    Davidson WF; Calkins C; Hügins A; Giese T; Holmes KL
    J Immunol; 1991 Jun; 146(12):4138-48. PubMed ID: 1674953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production.
    Andrade RM; Lima PG; Filho RG; Hygino J; Milczanowski SF; Andrade AF; Lauria C; Brindeiro R; Tanuri A; Bento CA
    AIDS; 2007 Aug; 21(13):1763-70. PubMed ID: 17690575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.